Publication Details
Abstract
Supplements such as Alpha Lipoic Acid are becoming more and more popular as more women look for natural remedies or prescription drugs to control their symptoms. Better health outcomes and an improved quality of life can result from combining these with a customized plan. Evaluation of the combined effects of metformin, and ALA, in PCOS in terms of weight loss, serum lipid profile, and insulin resistance is the goal of the current study. The randomized, single-blind, and actively controlled clinical trial was conducted in Babylon, Iraq, between September 2024 and March 2025. The participants were divided into two groups at random. Computer-generated random numbers were used for the random assignment. Glucophage (500 mg; Merck, West Drayton, UK) was administered once daily for 2 weeks followed by 2 times a day until end of study to patients in Group Met., while patients in Group Met.+ALA got metformin as in the first group plus ALA (600 mg, Batch no. 53642; neutec, Turkey) once/ day. Every treatment was administered for a total of twelve weeks. The average body mass index, cholesterol, triglycerides, and LDL all dramatically decreased after treatment, while HDL increased (p < 0.001). The effect of Met. plus ALA was significantly more pronounced than that of the other therapeutic modality (p < 0.05). Nevertheless, resistin serum levels were not substantially impacted by any of these treatment modalities (p > 0.05). In women with PCOS, alpha lipoic acid supplements are effective and safe ways to increase the results of metformin treatment in terms of weight loss and serum lipid profile improvement.